ArticleRSC advances2026
Rational design of click-assembled chiral dendrimers: anticancer activity and molecular dynamics study.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study details the rational design, synthesis, and biological evaluation of a range of chiral dendritic compounds created using modular copper(i)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry. We developed first-generation dendrimers (6-9) with systematically different degrees of chirality, comprising fully chiral, achiral, and mixed-chirality systems, as well as a multivalent second-generation dendrimer (12). The biological screening against human cancer cell lines (HCT-116, HepG-2, and MCF-7) revealed that the fully chiral first-generation dendrimer (9) was the most effective. Significantly, dendrimer (9) presented improved selectivity, as evidenced by a favorable therapeutic window with considerably reduced toxicity to normal WI-38 fibroblasts (IC
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.